CVM
CEL-SCI Corporation [CVM] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CVM Stock Summary
Top 10 Correlated ETFs
CVM
Top 10 Correlated Stocks
CVM
In the News
CVM Financial details
Company Rating
Neutral
Market Cap
87.99M
Income
-31.22M
Revenue
0
Book val./share
0.26
Cash/share
0.07
Dividend
-
Dividend %
-
Employees
43
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-3.34
Forward P/E
-
PEG
1.49
P/S
-
P/B
8.31
P/C
21.74
P/FCF
-5.32
Quick Ratio
0.74
Current Ratio
1.24
Debt / Equity
1.04
LT Debt / Equity
0.87
-
-
EPS (TTM)
-0.69
EPS next Y
-
EPS next Q
-
EPS this Y
-19.1%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.84%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-12.5%
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
-
Inst Own
10.86%
Inst Trans
0.91%
ROA
-108%
ROE
-176%
ROC
-1.26%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.04-3.23
52W High
-49.26%
52W Low
+52.21%
RSI
30
Rel Volume
0.42
Avg Volume
318.58K
Volume
134.48K
Perf Week
-8.86%
Perf Month
-33.24%
Perf Quarter
12.75%
Perf Half Y
33.52%
-
-
-
-
Beta
1.169
-
-
Volatility
0.06%, 0.21%
Prev Close
1.47%
Price
1.5221
Change
-1.16%
CVM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-09-30
| Metric | History | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0.02 | 0 | 0 | 0 | |
| Net income per share | -0.79 | -0.88 | -0.96 | -0.89 | -0.72 | |
| Operating cash flow per share | -0.52 | -0.42 | -0.46 | -0.42 | -0.51 | |
| Free cash flow per share | -0.53 | -0.49 | -0.68 | -0.44 | -0.52 | |
| Cash per share | 0.27 | 0.42 | 1.04 | 0.53 | 0.09 | |
| Book value per share | 0.16 | 0.54 | 1.39 | 0.75 | 0.3 | |
| Tangible book value per share | 0.15 | 0.53 | 1.38 | 0.74 | 0.29 | |
| Share holders equity per share | 0.16 | 0.54 | 1.39 | 0.75 | 0.3 | |
| Interest debt per share | 0.49 | 0.41 | 0.42 | 0.38 | 0.32 | |
| Market cap | 278.7M | 468.68M | 446.88M | 133.33M | 55.6M | |
| Enterprise value | 283.76M | 467.11M | 426.79M | 125.96M | 65.03M | |
| P/E ratio | -11.29 | -14.54 | -11.4 | -3.48 | -1.73 | |
| Price to sales ratio | 602.26 | 838.93 | 0 | 0 | 0 | |
| POCF ratio | -17.08 | -30.68 | -23.79 | -7.31 | -2.43 | |
| PFCF ratio | -16.73 | -26.08 | -16.06 | -7.05 | -2.39 | |
| P/B Ratio | 54.29 | 23.76 | 7.9 | 4.15 | 4.21 | |
| PTB ratio | 54.29 | 23.76 | 7.9 | 4.15 | 4.21 | |
| EV to sales | 613.2 | 836.12 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -15.09 | -18.04 | -13.22 | -3.92 | -2.36 | |
| EV to operating cash flow | -17.39 | -30.58 | -22.72 | -6.91 | -2.85 | |
| EV to free cash flow | -17.04 | -25.99 | -15.34 | -6.66 | -2.8 | |
| Earnings yield | -0.09 | -0.07 | -0.09 | -0.29 | -0.58 | |
| Free cash flow yield | -0.06 | -0.04 | -0.06 | -0.14 | -0.42 | |
| Debt to equity | 2.61 | 0.71 | 0.28 | 0.48 | 1.03 | |
| Debt to assets | 0.48 | 0.34 | 0.21 | 0.3 | 0.44 | |
| Net debt to EBITDA | -0.27 | 0.06 | 0.62 | 0.23 | -0.34 | |
| Current ratio | 3.25 | 4.15 | 11.5 | 5.45 | 1.24 | |
| Interest coverage | -11.24 | -27.82 | -31.49 | -33.36 | -46.6 | |
| Income quality | 0.74 | 0.5 | 0.52 | 0.5 | 0.71 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 17.28 | 20.95 | 0 | 0 | 0 | |
| Research and developement to revenue | 27.36 | 31.93 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0 | 0 | 0.01 | |
| Capex to operating cash flow | 0.02 | 0.18 | 0.48 | 0.04 | 0.02 | |
| Capex to revenue | -0.73 | -4.82 | 0 | 0 | 0 | |
| Capex to depreciation | -0.53 | -1.25 | -4.05 | -0.17 | -0.09 | |
| Stock based compensation to revenue | 9.88 | 18.39 | 0 | 0 | 0 | |
| Graham number | 1.71 | 3.25 | 5.49 | 3.86 | 2.2 | |
| ROIC | -0.7 | -0.65 | -0.44 | -0.6 | -0.8 | |
| Return on tangible assets | -0.9 | -0.8 | -0.52 | -0.76 | -1.06 | |
| Graham Net | -0.44 | -0.13 | 0.59 | 0.09 | -0.27 | |
| Working capital | 6.8M | 13.43M | 41.33M | 20.77M | 1.33M | |
| Tangible asset value | 4.82M | 19.41M | 56.26M | 31.95M | 13.02M | |
| Net current asset value | -12.67M | -3.11M | 25.94M | 7.08M | -10.39M | |
| Invested capital | 2.61 | 0.71 | 0.28 | 0.48 | 1.03 | |
| Average receivables | 90.71K | 58.84K | 54.92K | -973.4K | -1M | |
| Average payables | 3.67M | 1.8M | 1.85M | 1.65M | 1.81M | |
| Average inventory | 713.8K | 801.21K | 1.41M | 2M | 2.12M | |
| Days sales outstanding | 49.51 | 35.88 | 0 | 0 | 0 | |
| Days payables outstanding | 45.74K | 41.39K | 1.23K | 152.1 | 185.32 | |
| Days of inventory on hand | 22.56K | 16.78K | 1.47K | 188.14 | 207.3 | |
| Receivables turnover | 7.37 | 10.17 | 0 | 0 | 0 | |
| Payables turnover | 0.01 | 0.01 | 0.3 | 2.4 | 1.97 | |
| Inventory turnover | 0.02 | 0.02 | 0.25 | 1.94 | 1.76 | |
| ROE | -4.81 | -1.63 | -0.69 | -1.19 | -2.44 | |
| Capex per share | -0.01 | -0.07 | -0.22 | -0.02 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q1
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.19 | -0.2 | -0.19 | -0.16 | -0.14 | |
| Operating cash flow per share | -0.11 | -0.17 | -0.13 | -0.11 | -0.1 | |
| Free cash flow per share | -0.11 | -0.17 | -0.13 | -0.11 | -0.1 | |
| Cash per share | 0.41 | 0.23 | 0.12 | 0.09 | 0.07 | |
| Book value per share | 0.61 | 0.46 | 0.33 | 0.28 | 0.26 | |
| Tangible book value per share | 0.61 | 0.46 | 0.33 | 0.28 | 0.26 | |
| Share holders equity per share | 0.61 | 0.46 | 0.33 | 0.28 | 0.26 | |
| Interest debt per share | 0.35 | 0.34 | 0.32 | 0.29 | 0.27 | |
| Market cap | 102.08M | 101.13M | 106.65M | 58.73M | 131.84M | |
| Enterprise value | 98.96M | 105.54M | 115.54M | 68.15M | 141.7M | |
| P/E ratio | -3.04 | -2.97 | -3.19 | -1.92 | -4.91 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -21.88 | -13.54 | -18.82 | -11.64 | -26.97 | |
| PFCF ratio | -21.63 | -13.34 | -18.19 | -11.62 | -26.62 | |
| P/B Ratio | 3.84 | 5.02 | 7.21 | 4.44 | 10.42 | |
| PTB ratio | 3.84 | 5.02 | 7.21 | 4.44 | 10.42 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -14.74 | -14.66 | -16.05 | -10.57 | -25.73 | |
| EV to operating cash flow | -21.21 | -14.13 | -20.39 | -13.51 | -28.99 | |
| EV to free cash flow | -20.96 | -13.92 | -19.71 | -13.48 | -28.61 | |
| Earnings yield | -0.08 | -0.08 | -0.08 | -0.13 | -0.05 | |
| Free cash flow yield | -0.05 | -0.07 | -0.05 | -0.09 | -0.04 | |
| Debt to equity | 0.56 | 0.72 | 0.95 | 1.03 | 1.04 | |
| Debt to assets | 0.33 | 0.38 | 0.43 | 0.44 | 0.46 | |
| Net debt to EBITDA | 0.47 | -0.61 | -1.23 | -1.46 | -1.79 | |
| Current ratio | 4.3 | 2.37 | 1.46 | 1.24 | 1.26 | |
| Interest coverage | -50.07 | -51.4 | -45.04 | -41.05 | -32.81 | |
| Income quality | 0.59 | 0.9 | 0.68 | 0.66 | 0.73 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0.03 | 0 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.05 | -0.11 | -0.2 | -0.01 | -0.06 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.63 | 1.42 | 1.19 | 1.01 | 0.9 | |
| ROIC | -0.14 | -0.17 | -0.2 | -0.19 | -0.17 | |
| Return on tangible assets | -0.19 | -0.22 | -0.26 | -0.25 | -0.24 | |
| Graham Net | -0.01 | -0.19 | -0.29 | -0.26 | -0.28 | |
| Working capital | 15.66M | 7.26M | 2.44M | 1.33M | 1.29M | |
| Tangible asset value | 26.39M | 19.96M | 14.61M | 13.02M | 12.46M | |
| Net current asset value | 2.44M | -5.47M | -9.8M | -10.39M | -9.91M | |
| Invested capital | 0.56 | 0.72 | 0.95 | 1.03 | 1.04 | |
| Average receivables | -1.93M | -1.87M | -2M | -1.05M | -1.17M | |
| Average payables | 1.61M | 1.74M | 1.82M | 1.88M | 1.58M | |
| Average inventory | 1.93M | 1.87M | 2M | 2.18M | 2.3M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 144.91 | 171.74 | 158.59 | 181.12 | 102.52 | |
| Days of inventory on hand | 167.45 | 172.17 | 192.02 | 202.6 | 210.26 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.62 | 0.52 | 0.57 | 0.5 | 0.88 | |
| Inventory turnover | 0.54 | 0.52 | 0.47 | 0.44 | 0.43 | |
| ROE | -0.32 | -0.42 | -0.57 | -0.58 | -0.53 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CVM Frequently Asked Questions
What is CEL-SCI Corporation stock symbol ?
CEL-SCI Corporation is a US stock , located in Vienna of Va and trading under the symbol CVM
What is CEL-SCI Corporation stock quote today ?
CEL-SCI Corporation stock price is $1.5221 today.
Is CEL-SCI Corporation stock public?
Yes, CEL-SCI Corporation is a publicly traded company.
Company Profile
- Volume Average 318.58K
- Market Capitalization 87.99M
- Employee 43
- CEO Mr. Geert R. Kersten Esq.
- Headquarters Vienna,VA,US
- IPO Date 1983-12-08
-
Website
https://cel-sci.com 
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
